DOP2021000170A - Formulacion de anticuerpos terapeuticos - Google Patents

Formulacion de anticuerpos terapeuticos

Info

Publication number
DOP2021000170A
DOP2021000170A DO2021000170A DO2021000170A DOP2021000170A DO P2021000170 A DOP2021000170 A DO P2021000170A DO 2021000170 A DO2021000170 A DO 2021000170A DO 2021000170 A DO2021000170 A DO 2021000170A DO P2021000170 A DOP2021000170 A DO P2021000170A
Authority
DO
Dominican Republic
Prior art keywords
therapeutic antibodies
formulation
pharmaceutical formulations
aqueous pharmaceutical
stable aqueous
Prior art date
Application number
DO2021000170A
Other languages
English (en)
Inventor
John Corvari Vincent
Pisupati Karthik
Huaiqiu Shi Galen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2021000170A publication Critical patent/DOP2021000170A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Formulaciones farmacéuticas acuosas estables para anticuerpos terapéuticos y métodos de uso de dichas formulaciones farmacéuticas acuosas estables.
DO2021000170A 2019-02-18 2021-08-17 Formulacion de anticuerpos terapeuticos DOP2021000170A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962807006P 2019-02-18 2019-02-18
US201962880846P 2019-07-31 2019-07-31
US201962947198P 2019-12-12 2019-12-12
PCT/US2020/017594 WO2020172002A1 (en) 2019-02-18 2020-02-11 Therapeutic antibody formulation

Publications (1)

Publication Number Publication Date
DOP2021000170A true DOP2021000170A (es) 2021-09-30

Family

ID=72040829

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000170A DOP2021000170A (es) 2019-02-18 2021-08-17 Formulacion de anticuerpos terapeuticos

Country Status (21)

Country Link
US (2) US11634485B2 (es)
EP (1) EP3927729A4 (es)
JP (2) JP7266108B2 (es)
KR (1) KR20210114989A (es)
CN (1) CN113474360A (es)
AU (2) AU2020225202B2 (es)
BR (1) BR112021015034A2 (es)
CA (1) CA3129901A1 (es)
CL (1) CL2021002182A1 (es)
CO (1) CO2021010697A2 (es)
CR (1) CR20210435A (es)
DO (1) DOP2021000170A (es)
EC (1) ECSP21060917A (es)
IL (1) IL285134A (es)
JO (1) JOP20210229A1 (es)
MA (1) MA55033A (es)
MX (1) MX2021009851A (es)
PE (1) PE20212185A1 (es)
SG (1) SG11202108627SA (es)
UA (1) UA128098C2 (es)
WO (1) WO2020172002A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
JP2024502608A (ja) * 2021-01-08 2024-01-22 ラニア バイオセラピューティクス，インコーポレイテッド Ｉｌ－１７ａに対する中和抗体、その融合タンパク質およびその使用
CN118184793A (zh) * 2022-12-12 2024-06-14 江苏康缘瑞翱生物医药科技有限公司 一种靶向TNF-α与IL-17A的双特异性融合蛋白及其用途
CN116874596B (zh) * 2023-09-06 2023-11-24 南京佰抗生物科技有限公司 抗S100β蛋白的单克隆抗体及其制备方法和应用

Family Cites Families (358)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20050118163A1 (en) 2002-02-14 2005-06-02 Hidefumi Mizushima Antibody-containing solution pharmaceuticals
US7135180B2 (en) 2002-04-11 2006-11-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
KR20050011741A (ko) 2002-04-11 2005-01-29 메드이뮨 백신즈 인코포레이티드 분무 건조에 의한 생물학적 활성 물질의 보존
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AU2011226771B2 (en) 2002-06-14 2012-10-04 Medimmune, Llc Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
JP2005532395A (ja) 2002-07-02 2005-10-27 スミスクライン・ビーチャム・コーポレイション 新規な安定処方
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7055598B2 (en) 2002-08-26 2006-06-06 Halliburton Energy Services, Inc. Fluid flow control device and method for use of same
US20040247588A1 (en) 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
AU2003291527A1 (en) 2002-12-31 2004-07-29 Nektar Therapeutics Antibody-containing particles and compositions
US20040208869A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
EP1610820B2 (en) 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
KR101424624B1 (ko) 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
EP1629001A2 (en) 2003-06-05 2006-03-01 Genentech, Inc. Blys antagonists and uses thereof
PT1656170T (pt) 2003-08-12 2019-05-31 Lilly Co Eli Aparelho para dispensar medicação com parafusos com rosca tripla para vantagem mecânica
EP1698640B2 (en) 2003-10-01 2019-06-19 Kyowa Hakko Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
WO2005065709A2 (de) 2003-12-24 2005-07-21 Boehringer Ingelheim International Gmbh Gefriergetrocknete formulierung von antikörperkonjugaten
EP1712240B1 (en) 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
JP4874233B2 (ja) 2004-03-30 2012-02-15 イーライ リリー アンド カンパニー 最終用量の投与によって可能になるバネ駆動固定の特徴を持つ薬剤投与器具
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE602005022928D1 (de) 2004-11-30 2010-09-23 Abgenix Inc Antikörper gegen gpnmb und ihre verwendungen
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CN112480257A (zh) 2005-03-23 2021-03-12 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
US7785595B2 (en) 2005-04-18 2010-08-31 Yeda Research And Development Company Limited Stabilized anti-hepatitis B (HBV) antibody formulations
DK2390267T3 (da) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
SG162788A1 (en) * 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
AU2006259536A1 (en) 2005-06-15 2006-12-28 Schering Corporation Anti-IGF1R antibody formulations
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
KR101566393B1 (ko) 2005-08-03 2015-11-05 이뮤노젠 아이엔씨 면역접합체 제형
EP1916997B1 (en) 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
DOP2005000210A (es) 2005-10-19 2006-04-30 Genentech Inc Antibony formulations
US20070172520A1 (en) 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
AU2006318583A1 (en) 2005-11-22 2007-05-31 Wyeth Immunoglobulin fusion protein formulations
EP2481753B1 (en) 2005-12-13 2018-04-18 Eli Lilly and Company Anti-IL-17 Antibodies
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
ES2517420T3 (es) 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
KR20080098504A (ko) 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
JP2009526856A (ja) 2006-02-15 2009-07-23 イムクローン・リミテッド・ライアビリティ・カンパニー 抗体製剤
AU2007240732B2 (en) 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
CA2654794A1 (en) 2006-06-14 2007-12-21 Imclone Systems Incorporated Lyophilized formulations of anti-egfr antibodies
JPWO2008029908A1 (ja) 2006-09-07 2010-01-21 協和発酵キリン株式会社 抗体を含有する安定な凍結乾燥医薬製剤
KR20090060453A (ko) 2006-09-25 2009-06-12 메디뮨 엘엘씨 안정화된 항체 제제 및 그것의 용도
AU2007307107B2 (en) 2006-10-06 2011-11-03 Amgen Inc. Stable antibody formulations
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
DE102006053375A1 (de) 2006-11-10 2008-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mischung von Pulvern
BRPI0721097A2 (pt) 2006-12-11 2014-07-01 Hoffmann La Roche Formulação parenteral de anticorpo abeta
US20080213282A1 (en) 2006-12-21 2008-09-04 Jaby Jacob Formulations
CN101600457B (zh) 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
CA2675291C (en) 2007-01-11 2017-05-23 Novo Nordisk A/S Killer ig-like receptor (kir) antibodies, formulations, and uses thereof
JP2010522208A (ja) 2007-03-22 2010-07-01 イムクローン・リミテッド・ライアビリティ・カンパニー 安定な抗体処方物
EP2077859A4 (en) 2007-03-30 2010-11-24 Medimmune Llc ANTIBODY FORMULATION
TW200909005A (en) * 2007-06-14 2009-03-01 Elan Pharm Inc Lyophilized immunoglobulin formulations and methods of preparation
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US20110014676A1 (en) 2007-06-29 2011-01-20 Battelle Memorial Institute Protein stabilization
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
NZ602498A (en) 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
JP2011526356A (ja) 2008-06-26 2011-10-06 ワイス・エルエルシー 凍結乾燥サイクルのロバスト性（ｒｏｂｕｓｔｎｅｓｓ）方策
WO2010017296A1 (en) 2008-08-05 2010-02-11 Wyeth Lyophilization above collapse
US8263748B2 (en) 2008-08-27 2012-09-11 Schering Corporation Lyophilized formulations of engineered anti-IL-23p19 antibodies
ES2658596T3 (es) 2008-09-19 2018-03-12 Pfizer Inc. Formulación líquida estable de anticuerpos
PE20110302A1 (es) 2008-09-19 2011-05-21 Hoffmann La Roche Formulacion farmaceutica de un anticuerpo contra p-selectina
WO2010042705A1 (en) 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
BRPI0921845A2 (pt) 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
JP2012509270A (ja) 2008-11-17 2012-04-19 ジェネンテック， インコーポレイテッド 生理的条件下での高分子の凝集を低減するための方法及び製剤
EP2358395A4 (en) 2008-11-17 2013-11-20 Hoffmann La Roche METHOD AND FORMULATION FOR REDUCING THE AGGREGATION OF A MACROMOLECULUM UNDER PHYSIOLOGICAL CONDITIONS
US20120027772A1 (en) 2008-11-20 2012-02-02 Genentech, Inc. Therapeutic protein formulations
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US20100172862A1 (en) 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
JP2012511531A (ja) * 2008-12-09 2012-05-24 エフ．ホフマン−ラ ロシュ アーゲー 賦形剤不含抗体溶液を得るための方法
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
AU2010221099A1 (en) 2009-03-06 2011-09-22 Medimmune, Llc Humanized anti-CD19 antibody formulations
US9075049B2 (en) 2009-03-31 2015-07-07 Denka Seiken Co., Ltd. Immunoassay method and reagent therefor
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
WO2010148117A1 (en) 2009-06-17 2010-12-23 Scantibodies Laboratory, Inc. Therapeutic and diagnostic affinity purified specific polyclonal antibodies
WO2010148321A1 (en) 2009-06-18 2010-12-23 Wyeth Llc Slow dissolution method for reconstitution of lyophilized material
CN102695499A (zh) 2009-06-18 2012-09-26 惠氏有限责任公司 小模块免疫药物的冻干制剂
JP2012533548A (ja) 2009-07-14 2012-12-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組成物における黄色形成および過酸化物形成を阻害する方法
WO2011017070A1 (en) 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20110059079A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
RU2548772C2 (ru) 2009-11-20 2015-04-20 Биокон Лимитед Составы антитела
AU2010338305A1 (en) 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CN102821787B (zh) 2010-01-15 2015-07-29 麒麟-安姆根有限公司 抗体制剂和治疗方案
UA110026C2 (uk) 2010-03-01 2015-11-10 Пристрій для автоматичного виконання ін'єкції з механізмом затримки, який включає в себе пересувальний елемент подвійного призначення
CN102946861B (zh) 2010-03-01 2016-01-20 西托戴恩有限公司 浓缩蛋白制剂及其用途
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
SG183983A1 (en) 2010-03-17 2012-10-30 Abbott Res Bv Anti-nerve growth factor (ngf) antibody compositions
EP2568960B1 (en) 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
SG10201912670XA (en) 2010-05-14 2020-02-27 Amgen Inc High concentration antibody formulations
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
US8754195B2 (en) 2010-07-02 2014-06-17 Medimmune, Llc Antibody formulations
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
FR2962650B1 (fr) 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
WO2012037430A1 (en) 2010-09-17 2012-03-22 Abbott Laboratories Raman spectroscopy for bioprocess operations
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
CN104800844A (zh) 2010-11-05 2015-07-29 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法
TWI603739B (zh) 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2648750B1 (en) 2010-12-10 2017-01-25 Novartis AG Antibody formulation
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
EP2500035A1 (en) 2011-03-15 2012-09-19 Icon Genetics GmbH Pharmaceutical formulation containing immunglobulin
EP2686014A1 (en) 2011-03-16 2014-01-22 Sanofi Uses of a dual v region antibody-like protein
PL2691112T3 (pl) 2011-03-31 2018-09-28 Merck Sharp & Dohme Corp. Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
KR102014512B1 (ko) 2011-05-02 2019-08-26 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
KR102276161B1 (ko) 2011-10-25 2021-07-14 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
SI3091029T1 (sl) 2011-10-31 2023-03-31 F. Hoffmann - La Roche Ag Pripravki protiteles proti IL13
EP2788024A1 (en) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
KR20140121827A (ko) 2011-12-23 2014-10-16 메르사나 테라퓨틱스, 인코포레이티드 퓨마질린 유도체-phf 결합체의 약제학적 제형
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
CN104302350B (zh) 2012-03-07 2018-09-07 德卡产品有限公司 输液泵组件
NZ629261A (en) 2012-03-07 2017-08-25 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha antibodies
DK2822590T3 (en) * 2012-03-07 2017-01-23 Lilly Co Eli IL-17 antibody formulation
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
SG10201709555SA (en) 2012-05-18 2017-12-28 Genentech Inc High-concentration monoclonal antibody formulations
AR092325A1 (es) 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
US20150150982A1 (en) 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
WO2014031718A1 (en) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
KR102238677B1 (ko) * 2012-09-07 2021-04-12 코히러스 바이오사이언시즈, 인코포레이티드 아달리무맙의 안정한 수성 제형
BR112015008186A2 (pt) 2012-10-25 2017-09-19 Medimmune Llc formulação de um anticorpo estável e de baixa viscosidade
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
BR112015009924A2 (pt) 2012-11-01 2017-12-05 Abbvie Inc formulações de proteína imunoglobulina de domínio variável duplo estáveis
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
EP2931311A4 (en) 2012-12-13 2016-08-17 Merck Sharp & Dohme LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES
WO2014099636A1 (en) 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody
BR112015014853A2 (pt) 2012-12-21 2017-08-22 Glenmark Pharmaceuticals Sa Formulação farmacêutica, formulação farmacêutica liofilizada, uso de uma formulação farmacêutica e artigo de manufatura
US8877202B2 (en) 2013-02-07 2014-11-04 Immunomedics, Inc. Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
CA2904713A1 (en) 2013-03-11 2014-10-09 Amgen Inc. Protein formulations comprising darbepoetin
BR112015022210A8 (pt) 2013-03-13 2018-01-23 Genentech Inc formulações de anticorpo
CN105189546B (zh) 2013-03-13 2022-09-02 西雅图基因公司 环糊精和抗体-药物偶联物制剂
JP6541581B2 (ja) 2013-03-15 2019-07-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 低濃度抗体製剤
SG11201507430RA (en) 2013-03-15 2015-10-29 Abbvie Deutschland Anti-egfr antibody drug conjugate formulations
US11433029B2 (en) 2013-03-15 2022-09-06 Takeda Pharmaceutical Company Limited Formulation of an antibody and use thereof
JP2016515515A (ja) 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 抗プロラクチン受容体抗体製剤
US9700485B2 (en) * 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
MX2015016675A (es) 2013-06-04 2016-07-15 Vyome Biosciences Pvt Ltd Particulas recubiertas y composiciones que comprenden las mismas.
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CN110496099B (zh) 2013-09-11 2022-06-21 伊戈尔生物药品股份有限公司 包含粘度降低剂的液体蛋白质制剂
WO2015048520A1 (en) 2013-09-27 2015-04-02 Genentech, Inc. Anti-pdl1 antibody formulations
SG10201803178UA (en) 2013-10-24 2018-05-30 Astrazeneca Ab Stable, aqueous antibody formulations
WO2015075201A1 (en) 2013-11-21 2015-05-28 Genmab A/S Antibody-drug conjugate lyophilised formulation
WO2015110930A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
TW201542226A (zh) 2014-02-12 2015-11-16 Sanofi Sa 抗－ｉｌ－４／抗－ｉｌ－１３雙特異性抗體／聚麩胺酸配製物
US20150274819A1 (en) 2014-03-03 2015-10-01 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
WO2015138337A1 (en) 2014-03-09 2015-09-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
CA2941232C (en) 2014-03-11 2020-08-25 Green Cross Holdings Corporation Method for purifying immunoglobulin
ES2785375T3 (es) 2014-03-11 2020-10-06 Green Cross Holdings Corp Procedimiento de purificación de inmunoglobulina
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
WO2015153144A1 (en) 2014-03-31 2015-10-08 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
BR112016022345A2 (pt) 2014-03-31 2017-10-10 Genentech Inc terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
CA2944330A1 (en) 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
CA2942150A1 (en) 2014-04-07 2015-10-15 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates
JP2015209384A (ja) 2014-04-24 2015-11-24 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 医薬製剤
MX2016017025A (es) 2014-06-26 2017-08-08 Amgen Inc Formulaciones de proteinas.
EP3179985A1 (en) 2014-08-14 2017-06-21 Brown University Compositions for stabilizing and delivering proteins
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
BR112017003419A2 (pt) 2014-09-03 2017-11-28 Medimmune Ltd formulação de anticorpo anti-il-4r-alfa estável
EP3193932B1 (en) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
CA2964470A1 (en) 2014-10-17 2016-04-21 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
BR112017007393A2 (pt) 2014-10-18 2017-12-19 Pfizer composições de anticorpo anti-il-7r
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2016103093A1 (en) 2014-12-23 2016-06-30 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
EP3240571A4 (en) 2014-12-31 2018-06-13 NovelMed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
WO2016120753A1 (en) 2015-01-28 2016-08-04 Pfizer Inc. Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
PL3256154T3 (pl) 2015-02-09 2021-07-19 UCB Biopharma SRL Preparat farmaceutyczny zawierający przeciwciało
WO2016128564A1 (en) 2015-02-13 2016-08-18 Sanofi Stable liquid formulation for monoclonal antibodies
EP3283107B1 (en) 2015-04-17 2020-05-27 Bristol-Myers Squibb Company Compositions comprising a combination of ipilimumab and nivolumab
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
US20180201673A1 (en) 2015-07-16 2018-07-19 Eli Lilly And Company Treatment of pruritus
LT3769781T (lt) 2015-08-19 2023-06-12 Astrazeneca Ab Stabili anti-ifnar1 kompozicija
CN106474470B (zh) 2015-08-28 2020-05-22 江苏恒瑞医药股份有限公司 一种抗il-17a抗体的组合物
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
WO2017051273A1 (en) 2015-09-22 2017-03-30 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
CN106999591B (zh) 2015-09-28 2021-02-23 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体制剂及其在医药上的应用
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CN106620690A (zh) 2015-10-30 2017-05-10 上海抗体药物国家工程研究中心有限公司 一种稳定的抗体制剂
JP2018531980A (ja) 2015-10-30 2018-11-01 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体製剤
MX2018006139A (es) 2015-11-18 2019-03-14 Sio2 Medical Products Inc Envase farmaceutico para formulaciones oftalmicas.
US20190046641A1 (en) 2015-11-30 2019-02-14 Medimmune, Llc Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
MY195681A (en) 2015-12-07 2023-02-03 Merck Patent Gmbh Aqueous Pharmaceutical Formulation Comprising Anti-Pd-L1 Antibody Avelumab
EP3397281B1 (en) 2015-12-29 2020-09-09 Outlook Therapeutics, Inc. Buffered formulations of bevacizumab
RU2736830C2 (ru) 2016-01-12 2020-11-20 Др. Редди'С Лабораторис Лимитед Стабильная фармацевтическая композиция
WO2017121867A1 (en) 2016-01-13 2017-07-20 Genmab A/S Formulation for antibody and drug conjugate thereof
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
MA46681A (fr) * 2016-01-28 2019-09-11 Janssen Biotech Inc Anticorps bispécifiques anti-tnf-alpha/il-17a antibodies et anticorps anti-tnf-alpha et leurs procédés d'utilisation
AR103622A1 (es) 2016-02-05 2017-05-24 Ucb Biopharma Sprl Formulación farmaceutica
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
AU2017238651B2 (en) 2016-03-25 2024-06-13 Visterra, Inc. Formulation of antibody molecules to dengue virus
JP6992262B2 (ja) 2016-03-31 2022-02-15 東ソー株式会社 変性抗体測定試薬の製造方法
WO2017177265A1 (en) 2016-04-12 2017-10-19 Capsular Technologies Pty Ltd Injectable composition for delivery of a biologically active agent
JP2019511531A (ja) 2016-04-13 2019-04-25 メディミューン，エルエルシー 高濃度のタンパク質ベース治療薬を含有する医薬組成物における安定化化合物としてのアミノ酸の使用
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
TWI826351B (zh) 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
CN109475508A (zh) 2016-06-07 2019-03-15 阿瑞迪思医药品股份有限责任公司 具有增强的热稳定性的含有生物活性材料的速溶薄膜的制备方法
CN109415440B (zh) 2016-06-27 2022-12-06 莫佛塞斯公司 抗-cd19抗体制剂
AU2017287743C1 (en) 2016-06-30 2020-10-01 Celltrion Inc. Stable liquid pharmaceutical preparation
BR112019000135A2 (pt) 2016-07-05 2019-04-16 Sanofi formulações de anticorpo
US20190194311A1 (en) 2016-07-19 2019-06-27 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
FR3056912B1 (fr) 2016-09-30 2019-12-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Procede d'inactivation virale d'une preparation d'anticorps monoclonaux
MA46466A (fr) 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
IL310367A (en) 2016-10-07 2024-03-01 Regeneron Pharma A stable protein at room temperature that has been lyophilized
AU2017380842A1 (en) 2016-12-23 2019-07-11 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
CN110114078B (zh) 2016-12-28 2024-01-30 Jcr制药股份有限公司 冷冻干燥制剂
WO2018122053A1 (en) 2016-12-29 2018-07-05 F. Hoffmann-La Roche Ag Anti-angiopoietin-2 antibody formulation
CN108261544B (zh) 2016-12-30 2023-05-05 江苏太平洋美诺克生物药业股份有限公司 稳定的包含cd147单克隆抗体的药物制剂
CN108261391B (zh) 2016-12-30 2022-03-01 江苏太平洋美诺克生物药业有限公司 稳定的包含cd147单克隆抗体的药物制剂
JP7177777B2 (ja) 2017-01-11 2022-11-24 セルトリオン， インク． 安定した液体製剤
SI3570884T1 (sl) 2017-01-17 2021-02-26 Genentech, Inc. Subkutane formulacije protiteles HER2
RS62780B1 (sr) 2017-01-19 2022-01-31 Bayer Pharma AG Nova stabilna formulacija za fxia antitela
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
GB201703062D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
EP3797792A1 (en) 2017-03-01 2021-03-31 MedImmune Limited Formulations of anti-gm-csfralpha monoclonal antibody
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
BR112019018401A2 (pt) 2017-03-06 2020-04-07 Merck Patent Gmbh formulação aquosa de anticorpo anti-pd-l1
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
MX2019010895A (es) 2017-03-16 2019-11-05 Lg Chemical Ltd Formulacion liquida de anticuerpo anti-tnf alfa.
JP2020512359A (ja) 2017-03-29 2020-04-23 セルジーン コーポレイション Ｐｄ−１結合タンパク質を含む製剤及びそれを作製する方法
TW201836637A (zh) 2017-03-29 2018-10-16 持田製藥股份有限公司 含有抗體之液體製劑
WO2018179138A1 (ja) 2017-03-29 2018-10-04 持田製薬株式会社 抗体含有液体製剤
EP3603669B1 (en) 2017-03-31 2024-06-19 Meiji Seika Pharma Co., Ltd. Aqueous formulation, aqueous formulation in injector, antibody protein disaggregating agent, and antibody protein disaggregation method
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190255A1 (ar) 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
KR20200027494A (ko) 2017-07-10 2020-03-12 바이엘 파마 악티엔게젤샤프트 남성 및 여성 패턴 탈모를 위한 프로락틴 수용체 항체
CN107400164A (zh) 2017-07-18 2017-11-28 中山和芯生物技术有限公司 一种含蔗糖的生物制品稳定剂及其制备方法和应用
WO2019018640A1 (en) 2017-07-21 2019-01-24 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-GITREN ANTIBODIES AND USES THEREOF
AU2018306303A1 (en) 2017-07-25 2020-02-20 Elektrofi, Inc. Formation of particles including agents
EP3659586B1 (en) 2017-07-27 2023-06-21 Jiangsu Hengrui Medicine Co., Ltd. Sost antibody pharmaceutical composition and uses thereof
CN110869050B (zh) 2017-07-28 2024-07-02 豪夫迈·罗氏有限公司 双特异性抗体配制剂
EP3668544A1 (en) 2017-08-15 2020-06-24 Progenity, Inc. Treatment of inflammatory disease using ingestible device to release immune modulator
CA3073383C (en) 2017-08-23 2023-10-31 Daiichi Sankyo Company, Limited Antibody-drug conjugate preparation and lyophilization for same
MX2020002429A (es) 2017-09-05 2020-07-13 Merck Sharp & Dohme Compuestos para reducir la viscosidad de las formulaciones biologicas.
ES2938608T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
MA50670A (fr) 2017-09-29 2020-08-05 Janssen Biotech Inc Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose
JP7170983B2 (ja) 2017-10-13 2022-11-15 国立大学法人大阪大学 改善された保存安定性を有するタンパク質含有液体製剤およびその製造方法
CN109745559A (zh) 2017-11-01 2019-05-14 三生国健药业（上海）股份有限公司 抗人il-17a的单克隆抗体的液体制剂
GB201718888D0 (en) 2017-11-15 2017-12-27 Ucb Biopharma Sprl Method
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
EA202091130A1 (ru) 2017-11-29 2020-08-28 Протена Биосайенсис Лимитед Лиофилизованный препарат моноклонального антитела к транстиретину
CA3083971A1 (en) 2017-11-30 2019-06-06 Bio-Thera Solutions, Ltd. Liquid formulation of humanized antibody for treating il-6 related diseases
CN111356476B (zh) 2017-12-22 2023-03-10 江苏恒瑞医药股份有限公司 Lag-3抗体药物组合物及其用途
EP3749363A1 (en) 2018-02-08 2020-12-16 Amgen Inc. Low ph pharmaceutical antibody formulation
AU2019232625A1 (en) 2018-03-07 2020-09-17 Pfizer Inc. Anti-PD-1 antibody compositions
US11427639B2 (en) 2018-04-02 2022-08-30 Richter Gedeon Nyrt. Antibody-containing aqueous formulation and use thereof
US20210087250A1 (en) 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
CN112218895A (zh) 2018-04-10 2021-01-12 健玛保 用于癌症治疗的axl特异性抗体
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
BR112020021255A2 (pt) 2018-04-17 2021-02-02 Outlook Therapeutics, Inc. formulações tamponadas de bevacizumabe para uso no tratamento de doenças
AU2019258330A1 (en) 2018-04-25 2020-12-10 Medimmune Limited Formulations of human anti-PD-L1 antibodies
JOP20200275A1 (ar) 2018-05-10 2020-11-02 Regeneron Pharma صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز
CN112638941A (zh) 2018-05-14 2021-04-09 免疫医疗有限公司 针对lif的抗体及其剂量形式
CN110538321B (zh) 2018-05-29 2023-03-10 江苏恒瑞医药股份有限公司 一种cd47抗体药物组合物及其用途
SG11202011538RA (en) 2018-06-01 2020-12-30 Rakuten Medical Inc Phthalocyanine dye conjugate compositions
EP3801469A4 (en) 2018-06-07 2022-03-09 Merck Sharp & Dohme Corp. KIT OF CRITICAL REAGENTS IN THE FORM OF LYOSPHERES
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246313A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2019245373A1 (en) 2018-06-22 2019-12-26 Bioralix B.V. Formulations of biological polymers for oral administration
WO2020004368A1 (ja) 2018-06-25 2020-01-02 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
TW202011995A (zh) 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
CA3105541A1 (en) 2018-07-05 2020-01-09 Hangzhou Dac Biotech Co., Ltd Cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates
WO2020017901A1 (ko) 2018-07-19 2020-01-23 (주)셀트리온 안정한 액체 약제학적 제제
WO2020016417A1 (en) 2018-07-19 2020-01-23 Ichnos Sciences S.A. Liquid antibody formulation
WO2020041532A1 (en) 2018-08-21 2020-02-27 Sf17 Therapeutics, Inc. Compositions and methods for treating progressive neurodegenerative diseases
WO2020053301A1 (en) 2018-09-11 2020-03-19 Ichnos Sciences S.A. Compositions comprising a bispecific antibody, bufffer and one or more stabilizing agents
JP7475335B2 (ja) 2018-09-13 2024-04-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｓｆ－１ｒ抗体製剤
JP2022503886A (ja) 2018-10-05 2022-01-12 ファイブ プライム セラピューティクス， インコーポレイテッド 抗ｆｇｆｒ２抗体製剤
WO2020075746A1 (ja) 2018-10-10 2020-04-16 アステラス製薬株式会社 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物
MY195368A (en) 2018-10-12 2023-01-16 Hangzhou Dac Biotech Co Ltd A Conjugation Linker Containing 2,3-Diaminosuccinyl Group
CN113056482A (zh) 2018-10-18 2021-06-29 默沙东公司 抗rsv抗体的制剂及其使用方法
US20210353713A1 (en) 2018-10-26 2021-11-18 Amgen Inc. Formulations comprising a tris buffer and a protein
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
WO2020088346A1 (en) 2018-10-31 2020-05-07 Mycenax Biotech Inc. Aqueous pharmaceutical formulations
CA3118789A1 (en) 2018-11-06 2020-05-14 Genmab A/S Antibody formulation
EP3876978A4 (en) 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE
MX2021006430A (es) 2018-12-03 2021-09-14 Agensys Inc Composiciones farmacéuticas que comprenden conjugados de fármaco-anticuerpo anti-191p4d12 y métodos de uso de las mismas.
TWI820270B (zh) 2018-12-14 2023-11-01 德商莫菲西斯公司 抗體配方
EP3908606A4 (en) 2019-01-08 2022-11-23 H. Lundbeck A/S ACUTE AND RAPID TREATMENT OF HEADACHES USING ANTI-CGRP ANTIBODIES
JP2022523488A (ja) 2019-01-25 2022-04-25 エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド バイオ医薬製品の製造、包装、配送及び評価で使用される共通接触面
AU2020214626A1 (en) 2019-01-31 2021-09-16 Elektrofi, Inc. Particle formation and morphology
EA202192137A1 (ru) 2019-01-31 2021-10-25 Ханчжоу Дэк Биотек Ко., Лтд Конъюгат аматоксинового аналога с разветвленными линкерами
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
TW202102260A (zh) 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗ｉｌ－３３抗體之穩定調配物
EP4316521A3 (en) 2019-03-26 2024-04-10 RemeGen Co., Ltd. Anti-her2 antibody drug conjugate pharmaceutical preparation
CA3133652A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
EP3947448A4 (en) 2019-04-04 2023-02-01 Janssen Biotech, Inc. METHOD FOR ADMINISTRATION OF AN ANTI-IFN-ALPHA/-OMEGA ANTIBODY
CR20210521A (es) 2019-04-18 2022-04-01 Janssen Biotech Inc Glicoproteínas saliladas
EP3962942A1 (en) 2019-05-01 2022-03-09 Novo Nordisk A/S Anti-il-6 antibody formulation
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
CN111939267A (zh) 2019-05-17 2020-11-17 百奥泰生物制药股份有限公司 抗体-药物偶联物制剂、制备方法及应用
MA56033A (fr) 2019-05-24 2022-04-06 Sanofi Sa Méthodes de traitement de la sclérodermie généralisée
US20220227852A1 (en) 2019-05-28 2022-07-21 The General Hospital Corporation Apoe antibodies, fusion proteins and uses thereof
TW202112354A (zh) 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 遮蔽抗體調配物
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CN110124030A (zh) 2019-06-10 2019-08-16 通化东宝生物科技有限公司 一种苏金单抗注射液及其制备方法
JP2022541874A (ja) 2019-06-11 2022-09-28 サイファイ エス．ピー．エー． マイクロエマルション組成物
JP2022539076A (ja) 2019-06-24 2022-09-07 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 分岐連結体を有する細胞結合分子と細胞毒性剤との共役体
US20220273796A1 (en) 2019-07-19 2022-09-01 Ichnos Sciences SA Lyophilized antibody formulation
EP3766481A1 (en) 2019-07-19 2021-01-20 Ichnos Sciences SA Liquid antibody formulation
US20210030868A1 (en) 2019-07-29 2021-02-04 Cai Gu Huang Formulation of antibody based drugs for treating lung cancer by inhalation
JP2022547546A (ja) 2019-09-13 2022-11-14 エレクトロフィ，インコーポレイテッド 疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法
KR20220066318A (ko) 2019-09-20 2022-05-24 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용한 자가면역 질환의 치료 방법
CN110585430B (zh) 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
EP4037703A4 (en) 2019-10-02 2023-12-06 Alamab Therapeutics, Inc. ANTI-CONNEXIN ANTIBODIES FORMULATIONS
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
CN112891530B (zh) 2020-06-19 2021-08-24 北京东方百泰生物科技股份有限公司 一种抗il-17ra单克隆抗体的注射制剂

Also Published As

Publication number Publication date
US11634485B2 (en) 2023-04-25
JP7266108B2 (ja) 2023-04-27
BR112021015034A2 (pt) 2021-10-05
IL285134A (en) 2021-09-30
JP2022520857A (ja) 2022-04-01
PE20212185A1 (es) 2021-11-11
US20230183334A1 (en) 2023-06-15
MX2021009851A (es) 2021-09-10
SG11202108627SA (en) 2021-09-29
JOP20210229A1 (ar) 2023-01-30
CL2021002182A1 (es) 2022-03-18
AU2020225202A1 (en) 2021-08-12
CO2021010697A2 (es) 2021-10-29
WO2020172002A1 (en) 2020-08-27
EP3927729A4 (en) 2023-10-11
AU2023251529A1 (en) 2024-01-18
ECSP21060917A (es) 2021-09-30
CR20210435A (es) 2021-09-20
KR20210114989A (ko) 2021-09-24
EP3927729A1 (en) 2021-12-29
AU2020225202B2 (en) 2023-10-26
MA55033A (fr) 2021-12-29
CA3129901A1 (en) 2020-08-27
US20200262911A1 (en) 2020-08-20
UA128098C2 (uk) 2024-04-03
CN113474360A (zh) 2021-10-01
JP2023089190A (ja) 2023-06-27

Similar Documents

Publication Publication Date Title
DOP2021000170A (es) Formulacion de anticuerpos terapeuticos
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
BR112016006397A2 (pt) formulações de anticorpo de anti-pdl1
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
BR112015018087A8 (pt) composto, composição farmacêutica e uso
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
CO2019000643A2 (es) Formulaciones gastrorretentivas orales y usos de las mismas
BR112022001575A2 (pt) Formulações de anticorpos anti-pvrig e usos dos mesmos
BR112017004393A2 (pt) formulações de anticorpo
ECSP21021189A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
CU20210077A7 (es) Extractos bacterianos estables como fármacos
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
CL2022001486A1 (es) Formulaciones de anticuerpos anti-pd-l1.
CL2022001546A1 (es) Formulaciones líquidas de tasimelteón y métodos para su uso
CL2017002680A1 (es) Construcciones de calicheamicina y sus métodos de uso
MA53333A (fr) Formulations pharmaceutiques d'anticorps masqués
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
CL2018002010A1 (es) Derivados de indano y su uso en terapias.
BR112022009587A2 (pt) Anticorpo anti-pcsk9 e uso do mesmo
UY36958A (es) Compuestos para administración intracelular
BR112023002984A2 (pt) Formulações de anticorpo terapêutico
EA202191990A1 (ru) Состав терапевтического антитела